UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): January 28, 2015
VITAE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware (State or Other Jurisdiction of |
| 001-36617 (Commission File Number) |
| 04-3567753 (I.R.S. Employer Identification Number) |
502 West Office Center Drive
Fort Washington, PA 19034
(215) 461-2000
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On January 28, 2015, Vitae Pharmaceuticals, Inc. (“Vitae”) announced the closing of its previously announced underwritten public offering of 3,000,000 shares of Vitae’s common stock and the exercise by the underwriters in full of their option to purchase 450,000 additional shares of Vitae’s common stock. A copy of Vitae’s press release announcing the closing and the exercise of the underwriters’ option to purchase additional shares is attached hereto as Exhibit 99.1, and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
| Description |
99.1 |
| Vitae Pharmaceuticals, Inc. Press Release, dated January 28, 2015. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VITAE PHARMACEUTICALS, INC. | |
|
| |
|
| |
Date: January 28, 2015 | By: | /s/ Jeffrey S. Hatfield |
|
| Jeffrey S. Hatfield |
|
| Chief Executive Officer |